Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
56 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Emory Saint Joseph'S Hospital
Atlanta, Georgia, United States
- Emory University Hospital Midtown
Atlanta, Georgia, United States
- Emory University Hospital/winship Cancer Institute
Atlanta, Georgia, United States
- Grady Health System
Atlanta, Georgia, United States
- Augusta University Medical Center
Augusta, Georgia, United States
- Saint Alphonsus Cancer Care Center-Boise
Boise, Idaho, United States
- Saint Alphonsus Cancer Care Center-Caldwell
Caldwell, Idaho, United States
- Saint Alphonsus Cancer Care Center-Nampa
Nampa, Idaho, United States
- University of Kansas Cancer Center
Kansas City, Kansas, United States
- University of Kansas Cancer Center-West
Kansas City, Kansas, United States
- University of Kansas Cancer Center-Overland Park
Overland Park, Kansas, United States
- University of Kansas Hospital-Westwood Cancer Center
Westwood, Kansas, United States
- Saint Elizabeth Healthcare Edgewood
Edgewood, Kentucky, United States
- University of Maryland/greenebaum Cancer Center
Baltimore, Maryland, United States
- Um Upper Chesapeake Medical Center
Bel Air, Maryland, United States
- Central Maryland Radiation Oncology in Howard County
Columbia, Maryland, United States
- Um Baltimore Washington Medical Center/tate Cancer Center
Glen Burnie, Maryland, United States
- Mclaren Cancer Institute-Bay City
Bay City, Michigan, United States
- Mclaren Cancer Institute-Clarkston
Clarkston, Michigan, United States
- Michigan Healthcare Professionals Clarkston
Clarkston, Michigan, United States
- Wayne State University/karmanos Cancer Institute
Detroit, Michigan, United States
- Michigan Healthcare Professionals Farmington
Farmington Hills, Michigan, United States
- Weisberg Cancer Treatment Center
Farmington Hills, Michigan, United States
- Mclaren Cancer Institute-Flint
Flint, Michigan, United States
- Singh and Arora Hematology Oncology Pc
Flint, Michigan, United States
- Karmanos Cancer Institute at Mclaren Greater Lansing
Lansing, Michigan, United States
- Mid-Michigan Physicians-Lansing
Lansing, Michigan, United States
- Mclaren Cancer Institute-Lapeer Region
Lapeer, Michigan, United States
- Mclaren Cancer Institute-Macomb
Mount Clemens, Michigan, United States
- Mclaren Cancer Institute-Northern Michigan
Petoskey, Michigan, United States
- Mclaren-Port Huron
Port Huron, Michigan, United States
- Michigan Healthcare Professionals Troy
Troy, Michigan, United States
- Siteman Cancer Center at Saint Peters Hospital
City of Saint Peters, Missouri, United States
- Siteman Cancer Center at West County Hospital
Creve Coeur, Missouri, United States
- University of Kansas Cancer Center - North
Kansas City, Missouri, United States
- University of Kansas Cancer Center - Lee'S Summit
Lee's Summit, Missouri, United States
- University of Kansas Cancer Center at North Kansas City Hospital
North Kansas City, Missouri, United States
- Siteman Cancer Center at Christian Hospital
St Louis, Missouri, United States
- Siteman Cancer Center-South County
St Louis, Missouri, United States
- Washington University School of Medicine
St Louis, Missouri, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 28 Oct 2019
- Primary completion
- 26 Oct 2021
- Completion
- 4 Sept 2025
- Last update posted
- 23 Sept 2025
- Registered enrollment
- 26
- Registry id
- NCT03801902
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.